Guido J. R. Zaman

Guido J. R. Zaman

Auto-generated profile, based on publicly available information

Guido J. R. Zaman

Netherlands Translational Research Center B.V., Oss, the Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2015 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
AMA. R. R. Maia
A. R. R. Maia
JMJ. de Man
J. de Man
UBU. Boon
U. Boon
AJAniek Janssen
Aniek Janssen
JSJ.-Y. Song
J.-Y. Song
RMRené H. Medema
René H. Medema
Triple-negative breast cancers (TNBC) are considered the most aggressive type of breast cancer, for which no targeted therapy exists at the moment. These tumors are characterized by having a high degree of chromosome instability and often overexpress the spindle assembly checkpoint kinase TTK. To explore the potential of TTK inhibition as a targeted therapy in TNBC, we developed a highly potent and selective small molecule inhibitor of TTK, NTRC 0066-0. The compound is characterized by long residence time on the target and inhibits the proliferation of a wide variety of human cancer cell lines with potency in the same range as marketed cytotoxic agents. In cell lines and in mice, NTRC 0066-0 inhibits the phosphorylation of a TTK substrate and induces chromosome missegregation. NTRC 0066-0 inhibits tumor growth in MDA-MB-231 xenografts as a single agent after oral application. To address the effect of the inhibitor in breast cancer, we used a well-defined mouse model that spontaneously develops breast tumors that share key morphologic and molecular features with human TNBC. Our studies show that combination of NTRC 0066-0 with a therapeutic dose of docetaxel resulted in doubling of mouse survival and extended tumor remission, without toxicity. Furthermore, we observed that treatment efficacy is only achieved upon co-administration of the two compounds, which suggests a synergistic in vivo effect. Therefore, we propose TTK inhibition as a novel therapeutic target for neoadjuvant therapy in TNBC.

20 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JUJoost C. M. Uitdehaag
Joost C. M. Uitdehaag
JRJeroen A. D. M. de Roos
Jeroen A. D. M. de Roos
ADAntoon M. van Doornmalen
Antoon M. van Doornmalen
MPMartine B. W. Prinsen
Martine B. W. Prinsen
JMJos de Man
Jos de Man
GZGuido J. R. Zaman
Guido J. R. Zaman
The anti-proliferative activities of all twenty-five targeted kinase inhibitor drugs that are in clinical use were measured in two large assay panels: (1) a panel of proliferation assays of forty-four human cancer cell lines from diverse tumour tissue origins; and (2) a panel of more than 300 kinase enzyme activity assays. This study provides a head-on comparison of all kinase inhibitor drugs in use (status Nov. 2013), and for six of these drugs, the first kinome profiling data in the public domain. Correlation of drug activities with cancer gene mutations revealed novel drug sensitivity markers, suggesting that cancers dependent on mutant CTNNB1 will respond to trametinib and other MEK inhibitors, and cancers dependent on SMAD4 to small molecule EGFR inhibitor drugs. Comparison of cellular targeting efficacies reveals the most targeted inhibitors for EGFR, ABL1 and BRAF(V600E)-driven cell growth, and demonstrates that the best targeted agents combine high biochemical potency with good selectivity. For ABL1 inhibitors, we computationally deduce optimized kinase profiles for use in a next generation of drugs. Our study shows the power of combining biochemical and cellular profiling data in the evaluation of kinase inhibitor drug action.

1 November 2017 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
GZGuido J.R. Zaman
Guido J.R. Zaman
JRJeroen A.D.M. de Roos
Jeroen A.D.M. de Roos
MLMarion A.A. Libouban
Marion A.A. Libouban
MPMartine B.W. Prinsen
Martine B.W. Prinsen
JMJos de Man
Jos de Man
JUJoost C.M. Uitdehaag
Joost C.M. Uitdehaag
The spindle assembly checkpoint kinase TTK (Mps1) is a key regulator of chromosome segregation and is the subject of novel targeted therapy approaches by small-molecule inhibitors. Although the first TTK inhibitors have entered phase I dose escalating studies in combination with taxane chemotherapy, a patient stratification strategy is still missing. With the aim to identify a genomic biomarker to predict the response of tumor cells to TTK inhibitor therapy, we profiled a set of preclinical and clinical TTK inhibitors from different chemical series on a panel of 66 genetically characterized cell lines derived from different tumors (Oncolines). Cell lines harboring activating mutations in the CTNNB1 gene, encoding the Wnt pathway signaling regulator β-catenin, were on average up to five times more sensitive to TTK inhibitors than cell lines wild-type for CTNNB1. The association of CTNNB1-mutant status and increased cancer cell line sensitivity to TTK inhibition was confirmed with isogenic cell line pairs harboring either mutant or wild-type CTNNB1. Treatment of a xenograft model of a CTNNB1-mutant cell line with the TTK inhibitor NTRC 0066-0 resulted in complete inhibition of tumor growth. Mutations in CTNNB1 occur at relatively high frequency in endometrial cancer and hepatocellular carcinoma, which are known to express high TTK levels. We propose mutant CTNNB1 as a prognostic drug response biomarker, enabling the selection of patients most likely to respond to TTK inhibitor therapy in proof-of-concept clinical trials. Mol Cancer Ther; 16(11); 2609–17. ©2017 AACR.

1 July 2017 in Journal of Molecular Biology
Verified
Journal Article
Closed access
JUJoost C.M. Uitdehaag
Joost C.M. Uitdehaag
JMJos de Man
Jos de Man
NWNicole Willemsen-Seegers
Nicole Willemsen-Seegers
MPMartine B.W. Prinsen
Martine B.W. Prinsen
MLMarion A.A. Libouban
Marion A.A. Libouban
GZGuido J.R. Zaman
Guido J.R. Zaman

1 February 2017 in Journal of Molecular Biology
Verified
Journal Article
Closed access
NWNicole Willemsen-Seegers
Nicole Willemsen-Seegers
JUJoost C.M. Uitdehaag
Joost C.M. Uitdehaag
MPMartine B.W. Prinsen
Martine B.W. Prinsen
JVJudith R.F. de Vetter
Judith R.F. de Vetter
JMJos de Man
Jos de Man
GZGuido J.R. Zaman
Guido J.R. Zaman

15 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MLMarion A.A. Libouban
Marion A.A. Libouban
JRJeroen A.D.M. de Roos
Jeroen A.D.M. de Roos
JUJoost C.M. Uitdehaag
Joost C.M. Uitdehaag
NWNicole Willemsen-Seegers
Nicole Willemsen-Seegers
SMSara Mainardi
Sara Mainardi
GZGuido J.R. Zaman
Guido J.R. Zaman
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines